| Name | Title | Contact Details |
|---|
Haywood Vocational Opportunities is a Hazelwood, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VisionQuest Biomedical Inc. is a research and development company founded in 2007 with the objective of bringing affordable medical devices to the ophthalmic and diabetes care markets. VisionQuest has developed multiple medical devices with funding from the National Institutes of Health and is now looking to transfer those technologies to the commercial space. Our devices are currently being used in the United States and Latin America.
We deliver a total solution to improve the quality of life in addition to emergency response services. Life Support Medical delivers a team with over 100 years of combined experience in safety and security to deliver a customer experience unparalleled in our industry.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. From home to hospital and ER to OR, RapidAI is leading the next evolution of clinical decision-making and patient workflow, bringing the end-to-end patient journey into focus. Based on intelligence gained from over 4 million scans in more than 2000 hospitals in over 60 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible, saving lives, time and money.